Although it is known that non-alcoholic steatohepatitis (NASH) increases the risk of end-stage liver diseases such as cirrhosis and hepatocellular carcinoma, no pharmacologic therapy has yet been approved to treat it.
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 25% of the world’s adult population. In 20% of these patients, NAFLD further develops into non-alcoholic steatohepatitis (NASH), which itself represents a leading cause of progression to liver cirrhosis and hepatocellular carcinoma.
Although liver biopsy is the gold standard for the identification of non-alcoholic steatohepatitis (NASH), limits associated with its invasiveness justify research into non-invasive markers.
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide and a significant contributor to liver cirrhosis, transplantation, and hepatocellular carcinoma.
Non-alcoholic fatty liver disease (NAFLD) is currently the fastest-growing indicator for liver transplantation worldwide. Its status as a growing health concern further parallels the global rise of obesity.
Data from the Global Burden of Disease study indicates that non-alcoholic fatty liver disease (NAFLD) is the most rapidly increasing global contributor to chronic liver disease (CLD)-associated complications, which include the onset of cirrhosis and hepatocellular carcinoma.
It is known that traumatic muscle injury damages mitochondria, which may cause them to leak their contents into the cytoplasm and subsequently trigger calcium accumulation, cell death, endoplasmic reticulum stress, and the release of reactive oxygen species (ROS).
Walking speed (WS) is clinically recognized as a crucial vital sign. Associations between daily walking speed (DWS) and health outcomes have been underscored by a number of studies, which have further recognized it as an accurate predictor of dependency and mortality in elderly individuals. Despite this knowledge, very few studies have examined the link between DWS and frailty.
The association between metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD) has been well-characterised by recent literature. As such, patients with NAFLD are disproportionately affected by a range of comorbidities, which include obesity, dyslipidemia, type 2 diabetes mellitus (T2DM), and hypertension.
A non-invasive combined model termed FibroScan-aspartate aminotransferase (FAST) was recently proposed for the diagnosis of fibrotic non-alcoholic steatohepatitis (NASH). Conceptualised for patients with elevated non-alcoholic fatty liver disease (NAFLD) activity scores (≥4) and significant fibrosis
Cirrhosis is the end stage of a number of chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Characterised by the scarring of liver tissue, cirrhosis leads to significant hepatic tissue distortion, which may subsequently cause portal hypertension, hepatic synthetic dysfunction, and hepatocellular carcinoma.
Liver cancer has recently been defined as the third leading cause of cancer globally. Although its main aetiologies are hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol, and non-alcoholic steatohepatitis (NASH), the past decade has seen notable shifts in liver disease burden.